Monte Rosa Therapeutics/$GLUE
1D1W1MYTD1Y5YMAX
About Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
- Ticker
- $GLUE
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 173
- Headquarters
- Boston, United States
- Website
- www.monterosatx.com
GLUE Metrics
BasicAdvanced
$1.2B
-
-$1.74
1.53
-
Price and volume
Market cap
$1.2B
Beta
1.53
52-week high
$25.77
52-week low
$4.52
Average daily volume
1.3M
Financial strength
Current ratio
10.584
Quick ratio
10.494
Long term debt to equity
6.846
Total debt to equity
7.796
Profitability
EBITDA (TTM)
-173.728
Gross margin (TTM)
-465.18%
Net profit margin (TTM)
-560.85%
Operating margin (TTM)
-633.04%
Effective tax rate (TTM)
1.74%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-21.63%
Return on equity (TTM)
-42.66%
Valuation
Price to revenue (TTM)
45.961
Price to book
2.5
Price to tangible book (TTM)
2.5
Price to free cash flow (TTM)
-41.16
Free cash flow yield (TTM)
-2.43%
Free cash flow per share (TTM)
-0.347
Growth
Revenue change (TTM)
-83.86%
Earnings per share change (TTM)
-693.12%
3-year earnings per share growth (CAGR)
-12.20%
What the Analysts think about GLUE
Analyst ratings (Buy, Hold, Sell) for Monte Rosa Therapeutics stock.
GLUE Financial Performance
Revenues and expenses
GLUE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.